CARsgen Announces the Publication of a Novel CAR-T Technology that Improves the Efficacy of CAR-T cells Against Solid Tumors without Requiring Preconditioned Lymphodepletion

On August 17, 2020 CARsgen Therapeutics, a leader in developing novel CAR-T cell therapies against solid tumors, reported its publication of the 7×21 CAR-T technology in CLINICAL CANCER RESEARCH (Press release, Carsgen Therapeutics, AUG 17, 2020, View Source [SID1234563732]). The article is titled "Coexpression of IL-7 and CCL21 increases efficacy of CAR-T cells in solid tumors without requiring preconditioned lymphodepletion."

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Current challenges in CAR-T cell therapy for solid tumor malignancies include T cell survival, T cell infiltration, and antigen heterogeneity. CARsgen recently collaborated with State Key Laboratory of Oncogenes and Related Genes at the Shanghai Cancer Institute to overcome these obstacles. In this study, the CAR-T cells were engineered to co-express the cytokines IL-7 and CCL21 (7×21 CAR-T). Study results indicated the 7×21 CAR-T cells significantly outperformed the conventional CAR-T cells in cell proliferation and chemotaxis. Without the cyclophosphamide (CPA) precondition, the 7×21 CAR-T cells displayed superior therapeutic effects to both the conventional CAR-T cells and the 7×19 CAR-T cells, which co-expressed IL-7 and CCL19, in treating three different solid tumors. The 7×21 CAR-T cells could also efficiently inhibit the tumor growth of xenografts containing CLDN18.2-positive and CLDN18.2-negative tumor cells at a 1:1 ratio, and even resulting in complete tumor remission. The mechanistic study revealed that the 7×21 CAR T-cell treatment not only significantly improved the survival and infiltration of CAR-T cells and dendritic cells in vivo, but also led to less angiogenesis in tumors. These results support that the 7×21 CAR-T technology could be a promising therapeutic approach for the treatment of solid tumors.

The article may be found on following link: View Source